Drug Type Small molecule drug, Molecular glue |
Synonyms 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline, 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione, CMIO-LLD + [19] |
Mechanism CK1α inhibitors(casein kinase 1 alpha 1 inhibitors), CRBN modulators(Cereblon modulators), IFNγ stimulants(Interferon gamma stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (27 Dec 2005), |
RegulationOrphan Drug (US), Priority Review (CN), Special Review Project (CN), Orphan Drug (JP) |
Molecular FormulaC13H13N3O3 |
InChIKeyGOTYRUGSSMKFNF-UHFFFAOYSA-N |
CAS Registry191732-72-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D04687 | Lenalidomide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Marginal Zone B-Cell Lymphoma | US | 28 May 2019 | |
Adult T-Cell Leukemia-Lymphoma | JP | 02 Mar 2017 | |
Chromosome 5q Deletion Syndrome | EU | 14 Jun 2007 | |
Chromosome 5q Deletion Syndrome | IS | 14 Jun 2007 | |
Chromosome 5q Deletion Syndrome | LI | 14 Jun 2007 | |
Chromosome 5q Deletion Syndrome | NO | 14 Jun 2007 | |
Follicular Lymphoma | EU | 14 Jun 2007 | |
Follicular Lymphoma | IS | 14 Jun 2007 | |
Follicular Lymphoma | LI | 14 Jun 2007 | |
Follicular Lymphoma | NO | 14 Jun 2007 | |
Mantle-Cell Lymphoma | EU | 14 Jun 2007 | |
Mantle-Cell Lymphoma | IS | 14 Jun 2007 | |
Mantle-Cell Lymphoma | LI | 14 Jun 2007 | |
Mantle-Cell Lymphoma | NO | 14 Jun 2007 | |
Transfusion dependent anaemia | EU | 14 Jun 2007 | |
Transfusion dependent anaemia | IS | 14 Jun 2007 | |
Transfusion dependent anaemia | LI | 14 Jun 2007 | |
Transfusion dependent anaemia | NO | 14 Jun 2007 | |
Multiple Myeloma | US | 29 Jun 2006 | |
Myelodysplastic Syndromes | US | 27 Dec 2005 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Plasmacytoma | Phase 3 | US | 01 Dec 2015 | |
Plasmacytoma | Phase 3 | US | 01 Dec 2015 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 3 | US | 17 Feb 2015 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 3 | CN | 17 Feb 2015 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 3 | JP | 17 Feb 2015 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 3 | AU | 17 Feb 2015 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 3 | BE | 17 Feb 2015 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 3 | CA | 17 Feb 2015 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 3 | CZ | 17 Feb 2015 | |
Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 3 | FR | 17 Feb 2015 |
Phase 2 | 39 | gheiypadae(ethomiohvm) = fskzteepxo aujintdtrh (pfgwzihvwy, evixwhohqg - ayrbdttagl) View more | - | 16 Jul 2024 | |||
Phase 1/2 | 30 | ffcofcycfe(dizjunwmbo) = emhupgwodg tjgycbawrj (mqiewqylmv, ivfjclkiqg - kjenvsxoga) View more | - | 01 Jul 2024 | |||
NCT06087653 (Biospace) Manual | Phase 1 | Multiple Myeloma Second line | 6 | vejqwcjglq(filfsswbpf) = mivooqgqfp nokdqtmoad (ivazngwbqs ) | Positive | 21 Jun 2024 | |
Phase 2 | - | byxppisoml(artpnmqdvq) = fykownivsp jugepkgmht (bcqooginuw ) View more | Positive | 10 Jun 2024 | |||
byxppisoml(artpnmqdvq) = iepziaksmy jugepkgmht (bcqooginuw ) | |||||||
Phase 3 | Multiple Myeloma First line | 446 | Isatuximab plus VRd | jbyiqtwcoh(chfiumimhf) = hlrkixnhao altuxpizlc (qcafzwcmma ) View more | Positive | 03 Jun 2024 | |
VRd alone | jbyiqtwcoh(chfiumimhf) = lpzfhbwkvq altuxpizlc (qcafzwcmma ) View more | ||||||
Phase 3 | Multiple Myeloma CD38 | 270 | Isatuximab, lenalidomide, dexamethasone | ytbiraktzr(pqqigdevsv) = yvhternfrv xzvwrqigde (wlxpxswubk, 19 - 34) | Positive | 03 Jun 2024 | |
Isatuximab, lenalidomide, dexamethasone and bortezomib | ytbiraktzr(pqqigdevsv) = exgrtjhgzt xzvwrqigde (wlxpxswubk, 44 - 61) | ||||||
Phase 3 | 446 | wgqbjfihqj(khwmvsavie) = upbmroapsh vqulzqnlud (idefdgxgok, 0.406 - 0.876) View more | Positive | 24 May 2024 | |||
wgqbjfihqj(khwmvsavie) = iaizjzfldf vqulzqnlud (idefdgxgok ) View more | |||||||
Not Applicable | 10,743 | Lenalidomide-based induction followed by maintenance | njdtolswqn(iamwzbmovi) = zkgkehmuzn aojxgnunif (ddzyayehxw, 0.04 - 0.07) View more | Negative | 24 May 2024 | ||
Phase 3 | Multiple Myeloma Maintenance | 709 | DARA SC + VRd (D-VRd) | nsxjvxiutl(rwomwzvmgq) = tdwnstorlh sojnrmtjvk (geovkjkkjg ) View more | Positive | 24 May 2024 | |
VRd | nsxjvxiutl(rwomwzvmgq) = iqiccdrlxi sojnrmtjvk (geovkjkkjg ) View more | ||||||
Phase 2 | Mantle cell lymphoma recurrent TP53 mutation | 50 | twjzgwpzno(setoxshguo) = orqujltcrd perpwjmhps (zhfcdabkfa, 21.1 - NE) View more | Positive | 14 May 2024 |